2,331 reports of this reaction
1.5% of all PEMBROLIZUMAB reports
#16 most reported adverse reaction
INTERSTITIAL LUNG DISEASE is the #16 most commonly reported adverse reaction for PEMBROLIZUMAB, manufactured by Merck Sharp & Dohme LLC. There are 2,331 FDA adverse event reports linking PEMBROLIZUMAB to INTERSTITIAL LUNG DISEASE. This represents approximately 1.5% of all 152,954 adverse event reports for this drug.
PEMBROLIZUMAB has an overall safety score of 88 out of 100. Patients taking PEMBROLIZUMAB who experience interstitial lung disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INTERSTITIAL LUNG DISEASE is a less commonly reported adverse event for PEMBROLIZUMAB, but still significant enough to appear in the safety profile.
In addition to interstitial lung disease, the following adverse reactions have been reported for PEMBROLIZUMAB:
The following drugs have also been linked to interstitial lung disease in FDA adverse event reports:
INTERSTITIAL LUNG DISEASE has been reported as an adverse event in 2,331 FDA reports for PEMBROLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INTERSTITIAL LUNG DISEASE accounts for approximately 1.5% of all adverse event reports for PEMBROLIZUMAB, making it a notable side effect.
If you experience interstitial lung disease while taking PEMBROLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.